Market Snapshot

BSE Sensex: 73319.55 0.25%
BSE 500: 32839.65 0.08%
BSE 200: 10347.1 0.11%
BSE 100: 23846.26 0.16%
BSE BANKEX: 58009.41 0.22%
BSE IT: 29288.17 2.42%
Nifty 50: 22713.1 0.15%
Nifty 500: 20938.35 0.02%
Nifty 200: 12728 0.06%
Nifty 100: 23304.2 0.14%
Nifty Midcap 100: 53677.05 -0.26%
Nifty Small 100: 15650.5 -0.38%
Nifty IT: 30441.45 2.60%
Nifty PSU Bank: 8134.4 -0.37%

News:

Marico gains on healthy revenu...
Maha Rashtra Apex Corporation ...
Volumes soar at Latent View An...
Texmaco Rail & Engineering bag...
Sai Silks turnover climbs 5% Y...

Syngene International Ltd Share Price – NSE / BSE
Healthcare, Small Cap

Invest

02 Apr 2026 | 04:14 PM

391.10

-5.30 (-1.34%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-45.99%

Return (1Y)

Underperformed Nifty 500 by 44.45%
More Volatile

1.97%

Standard Deviation (1Y)

Higher than Nifty 500 by 1.05%
Inconsistent Performer

3/12

Months

underperformed Nifty 500
AxisDirect View

No View

52 Week High-Low

760

380

News & Announcements

Syngene Intl tumbles after MD & CEO Peter Bains resigns; Siddharth Mittal to take charge
4 days ago

Syngene Intl tumbles after MD & CEO Peter Bains resigns; Siddharth Mittal to take charge

30 - Mar - 2026 12:00 | 4 days ago

Following his exit, the board has approved the appointment of Siddharth Mittal as an additional director, designated as MD & CEO with effect from 1 July 2026.
Mittal previously served as MD and CEO of Biocon. He joined the company in May 2013 and served as president & chief financial officer until November 2019. He brings over two decades of experience in strategic finance, M&A, and general management.
During his tenure, he contributed to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under Siddharth?s leadership, Biocon moved decisively into complex peptides and GLP-1 therapies, stepping into one of the most strategically significant segments in modern pharma. He also led the company?s entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets.
Meanwhile, the board has also approved the redesignation of Kiran Mazumdar-Shaw from non-executive chairperson to executive chairperson, subject to shareholders? approval.
Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
The company?s consolidated net profit declined 88.56% to Rs 15 crore on 2.82% fall in revenue from operations to Rs 917.1 crore in Q3 FY26 over Q3 FY25.
Powered by Capital Market - Live News
Syngene International consolidated net profit declines 88.56% in the December 2025 quarter
70 days ago

Syngene International consolidated net profit declines 88.56% in the December 2025 quarter

23 - Jan - 2026 12:00 | 70 days ago

Net profit of Syngene International declined 88.56% to Rs 15.00 crore in the quarter ended December 2025 as against Rs 131.10 crore during the previous quarter ended December 2024. Sales declined 2.82% to Rs 917.10 crore in the quarter ended December 2025 as against Rs 943.70 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 917.10 943.70 -3

OPM % 22.81 30.05 -

PBDT 212.70 289.50 -27

PBT 99.00 180.80 -45

NP 15.00 131.10 -89

Powered by Capital Market - Live News
Syngene International to conduct board meeting
84 days ago

Syngene International to conduct board meeting

09 - Jan - 2026 12:00 | 84 days ago

Syngene International will hold a meeting of the Board of Directors of the Company on 22 January 2026.
Powered by Capital Market - Live News
Syngene International consolidated net profit declines 36.76% in the September 2025 quarter
148 days ago

Syngene International consolidated net profit declines 36.76% in the September 2025 quarter

06 - Nov - 2025 12:00 | 148 days ago

Net profit of Syngene International declined 36.76% to Rs 67.10 crore in the quarter ended September 2025 as against Rs 106.10 crore during the previous quarter ended September 2024. Sales rose 2.20% to Rs 910.60 crore in the quarter ended September 2025 as against Rs 891.00 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 910.60 891.00 2

OPM % 21.91 27.47 -

PBDT 201.70 248.20 -19

PBT 85.20 137.30 -38

NP 67.10 106.10 -37

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Syngene International Ltd is trading very close to its 52 Week Low
FII shareholding in Syngene International Ltd has decreased by -8.27% since past 3 Months
MF shareholding in Syngene International Ltd has increased by 7.05% since past 3 Months
FII shareholding in Syngene International Ltd has decreased by -27.52% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	917.10	943.70	-3
OPM %	22.81	30.05	-
PBDT	212.70	289.50	-27
PBT	99.00	180.80	-45
NP	15.00	131.10	-89

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	910.60	891.00	2
OPM %	21.91	27.47	-
PBDT	201.70	248.20	-19
PBT	85.20	137.30	-38
NP	67.10	106.10	-37

General Notifications

My Notifications

Research Notifications

Syngene International Ltd Share Price – NSE / BSE Healthcare, Small Cap

391.10 -5.30 (-1.34%)

News & Announcements

Price vs Volume

Stock Trivia

Syngene International Ltd Share Price – NSE / BSE
Healthcare, Small Cap

391.10

-5.30 (-1.34%)